Close Menu

NIPD Genetics

The Cyprus-based company has been offering a cell-free DNA-based noninvasive prenatal test for fetal aneuploidies, called Veracity, since 2015.

Last month, the Cyprus-based genetic diagnostics company launched a number of hereditary cancer and somatic tumor sequencing panels, its first tests for oncology.

The companies will bring NIPD Genetics' Veracity and Veragene noninvasive prenatal tests to Medicover's markets, as well as developing new genetic tests.

The firm plans to include seven subchromosomal alterations to its NIPT by the end of March and wants to expand into the liquid biopsy market.

The company has also expanded its current Veracity NIPT to sex chromosomal aneuplodies and twin pregnancies, and plans to offer microdeletion testing next year.

The Cyprus-based company recently moved into new premises, increased its headcount, and received CAP accreditation for its laboratory.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.